Shineco, Inc. Attends MEDICA 2022 Düsseldorf Germany
29 Noviembre 2022 - 8:00AM
Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a
producer and distributor of Chinese herbal medicines, organic
agricultural and other biotech products, announced that the
Company’s controlling affiliate Changzhou Biowin Pharmaceutical
Co., Ltd. ("CBP"), a Chinese biotechnology company focusing on
in-vitro diagnostic product research and development (“R&D”)
and high-tech biomedical products manufacturing, attended MEDICA
2022 in Düsseldorf, Germany from November 14 to 17, 2022. MEDICA
2022 is one of the world's largest medical trade fair held annually
for medical technology, electromedical equipment, laboratory
equipment, diagnostics and pharmaceuticals. With an exhibition area
of more than 108,000 square meters, the trade fair attracts
visitors and exhibitors from approximately 70 countries worldwide.
As the first public appearance after joining
Shineco, Dr. Marvin Liu, the Chairman of CBP attended MEDICA 2022
with CBP team and displayed a number of innovative products,
including COVID-19 home self-test and special testing products,
monkeypox virus testing series products, cardiovascular testing and
drug testing products, and the world's leading stool sampling
device that can complete stool sampling during the defecation
process with intellectual property protection. The CBP team
demonstrated its competitive strengths to experts, scholars, and
partners in the field of medical testing globally. CBP's innovative
products and solutions attracted the attention of experts and
potential customers.
Dr. Marvin Liu, commented: “With the capital and
international resource advantages of Shineco, CBP has gained more
opportunities to allow more and more people to understand and know
CBP's cutting-edge technology and innovative ideas worldwide. CBP
will continue to provide better in vitro diagnostic products for
the global market through continuous pursuit of technological
innovation and high quality and bring greater value to
shareholders.”
About
Shineco, Inc.
Incorporated in Delaware in August 1997 and
headquartered in Beijing, China, Shineco is a holding company.
Utilizing modern engineering technologies and biotechnologies,
Shineco produces, among other products, Chinese herbal medicines,
organic agricultural produce, and specialized textiles. For more
information about Shineco, please visit www.biosisi.com.
Forward-Looking Statements
This news release contains “forward-looking
statements” within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. These forward-looking statements can be
identified by terminology such as “may”, “will”, “should”, “could”,
“intend”, “expect”, “plan”, “budget”, “forecast”, “anticipate”,
“believe”, “estimate”, “predict”, “potential”, “continue”,
“evaluating” or similar words. Forward-looking statements should
not be relied upon because they are neither historical facts nor
assurances of future performance. Instead, they are based only on
our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, projections,
anticipated events and trends, the economy and other future
conditions. Examples of forward-looking statements include, among
others, statements we make regarding the innovativeness and market
position of our products and services, our stool sampling device
being the world's leading stool sampling device that can complete
stool sampling during the defecation process with intellectual
property protection, our competitive strengths, and our expectation
to provide better in vitro diagnostic products for the global
market through continuous pursuit of technological innovation and
high quality and bring greater value to shareholders. You are
cautioned not to rely on any forward-looking statements. Actual
results may differ materially from historical results or those
indicated by the forward-looking statements as a result of a
variety of factors including, but not limited to, risks and
uncertainties associated with the Company’s ability to raise
additional funding, its ability to maintain and grow its business,
variability of operating results, its ability to maintain and
enhance its brand, its development and introduction of new products
and services, the successful integration of acquired companies,
technologies and assets into its portfolio of products and
services, marketing and other business development initiatives,
competition in the industry, general government regulations,
economic conditions, the impact of the COVID-19 pandemic,
dependence on key personnel, the ability to attract, hire and
retain personnel who possess the technical skills and experience
necessary to meet the requirements of its clients, and its ability
to protect its intellectual property. Shineco encourages you to
review other factors that may affect its future results in its
registration statements and in its other filings with the
Securities and Exchange Commission. The forward-looking statements
in this press release are based only on information currently
available to us and speak only as of the date of this press
release, and Shineco assumes no obligation to update any
forward-looking statements except as required by the applicable
rules and regulations.
For more information, please contact:
Tina XiaoAscent Investor Relations LLCPhone:
+1-917-609-0333Email: tina.xiao@ascent-ir.com
Shineco (NASDAQ:SISI)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Shineco (NASDAQ:SISI)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024